Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
Volume 6.99M
Average 14.09M
Dividends
Iovance Biotherapeutics, Inc. dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does Iovance Biotherapeutics, Inc. compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
Genmab A/S NASDAQ:GMAB | $31.67B | 0.00% | $0.00 | 0.00% | 0.38% |
BioNTech SE NASDAQ:BNTX | $21.22B | 0.00% | $0.00 | 0.00% | 0.64% |
ImmunityBio, Inc. NASDAQ:IBRX | $6.40B | 0.00% | $0.00 | 0.00% | 0.00% |
Legend Biotech Corporation NASDAQ:LEGN | $3.24B | 0.00% | $0.00 | 0.00% | 0.00% |
Immunome, Inc. NASDAQ:IMNM | $2.22B | 0.00% | $0.00 | 0.00% | 0.00% |
Replimune Group, Inc. NASDAQ:REPL | $2.08B | 0.00% | $0.00 | 0.00% | 0.00% |
Immunocore Holdings plc NASDAQ:IMCR | $1.55B | 0.00% | $0.00 | 0.00% | 0.00% |
Shattuck Labs, Inc. NASDAQ:STTK | $473.57M | 0.00% | $0.00 | 0.00% | 0.00% |
Fate Therapeutics, Inc. NASDAQ:FATE | $149.20M | 0.00% | $0.00 | 0.00% | 0.00% |
ALX Oncology Holdings Inc. NASDAQ:ALXO | $143.81M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about IOVA's dividend, answered from reported figures.
Does IOVA stock pay dividends?
Iovance Biotherapeutics, Inc. (IOVA) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is IOVA's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.